In particular, metformin-activated AMPK appears to be effective in suppressing PD-L1/PD-1 signaling pathways via endoplasmic-reticulum-associated degradation of PD-L1 in different in vitro and in vivo tumor models [172]. Here, CD274 is linked to neoplasm.